Home » Stocks » Zymeworks

Zymeworks Inc. (ZYME)

Stock Price: $34.72 USD -2.56 (-6.87%)
Updated Jul 9, 2020 10:02 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.58B
Revenue (ttm) 25.89M
Net Income (ttm) -162.93M
Shares Out 45.54M
EPS (ttm) -3.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $34.72
Previous Close $37.28
Change ($) -2.56
Change (%) -6.87%
Day's Open 36.04
Day's Range 34.24 - 36.24
Day's Volume 285,956
52-Week Range 20.33 - 52.75

More Stats

Market Cap 1.58B
Enterprise Value 1.10B
Earnings Date (est) Jul 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.54M
Float 36.20M
EPS (basic) -4.03
EPS (diluted) -3.87
FCF / Share -2.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.86M
Short Ratio 4.02
Short % of Float 4.11%
Beta 1.15
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 61.08
PB Ratio 3.14
Revenue 25.89M
Operating Income -172.63M
Net Income -162.93M
Free Cash Flow -104.86M
Net Cash 478.66M
Net Cash / Share 10.51
Gross Margin -333.58%
Operating Margin -666.83%
Profit Margin -629.40%
FCF Margin -405.05%
ROA -24.57%
ROE -47.06%
ROIC -95.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(57.89% upside)
Current: 34.72
Target: 54.82
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-44.28%2.43%370.18%13.96%478.44%-
Gross Profit29.5453.0251.7611.019.661.67
Operating Income-151-33.36-9.47-37.86-19.96-12.75
Net Income-145-36.56-10.41-33.81-19.17-12.94
Shares Outstanding38.0229.0921.2512.7411.277.32
Earnings Per Share-3.83-1.26-0.64-2.65-1.70-1.77
Operating Cash Flow-81.8524.180.22-35.25-22.17-7.02
Capital Expenditures-6.32-0.80-2.02-4.43-0.63-0.08
Free Cash Flow-88.1823.37-1.80-39.67-22.80-7.10
Cash & Equivalents29920087.8040.2615.160.00
Total Debt6.88--4.42--
Net Cash / Debt29220087.8035.8415.160.00
Book Value2461801169.0018.24-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zymeworks Inc.
Country Canada
Employees 267
CEO Ali Tehrani

Stock Information

Ticker Symbol ZYME
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: ZYME
IPO Date April 28, 2017


Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and collaboration with Applied BioMath, LLC. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.